This inventor holds 1 USPTO granted patent. Top assignee: Novosis Pharma Ag. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Axel Stierle: Innovator in Transdermal Drug Delivery Systems
Introduction
Axel Stierle is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of transdermal systems for drug delivery. His innovative approach aims to enhance the efficacy of anti-emetic treatments.
Latest Patents
Stierle holds a patent for a transdermal system designed for the release of 5-HT3 receptor antagonists. This invention is characterized by its unique composition, which includes a 5-HT3 receptor antagonist as the active agent, tea tree oil, a water-miscible solvent, and water. This formulation aims to improve the delivery and effectiveness of anti-emetic treatments.
Career Highlights
Stierle is associated with Novosis Pharma AG, a company focused on advancing pharmaceutical innovations. His work at Novosis Pharma AG has allowed him to explore new avenues in drug delivery systems, contributing to the overall improvement of patient care.
Collaborations
Stierle collaborates with Wilfried Fischer, a fellow innovator in the field. Their partnership has fostered a creative environment that encourages the development of groundbreaking solutions in pharmaceutical technology.
Conclusion
Axel Stierle's contributions to transdermal drug delivery systems exemplify the importance of innovation in the pharmaceutical industry. His work not only enhances treatment options but also paves the way for future advancements in drug delivery technologies.